Companies
Aizon
produces an AI-driven manufacturing-intelligence platform for pharma production combining analytics with compliance functions, with a documented strategic partnership (Sequence) extending AI-powered solutions across biopharmaceutical manufacturing.
- Country
- United States
US
Coverage
| EU | US | |
|---|---|---|
| digital-it | ✓ | ✓ |
Regulatorsfdaema
Verifiable facts
| Fact | Value | Source |
|---|---|---|
| Funding | $44.1M total funding raised across 4 rounds | startupintros.com |
| Revenue | estimated between $12.6M and $25.1M annually medium confidence | getlatka.com · healthydata.science |
| Headcount | 131 to 159 employees | getlatka.com |
| Certification | ISO 9001, ISO 27001, ISO 27017, and SOC 2 certifications | healthydata.science · aizon.ai |
| Regulatory approval | Platform supports compliance with FDA 21 CFR Part 11 and EU GMP Annex 11, designed against GAMP 5 principles | aizon.ai |
| Production site | San Francisco, USA and Barcelona, Spain | startupintros.com · aizon.ai |
| Capacity | platform is scalable, supports from tens to more than 1,000+ batches per year medium confidence | connect.aizon.ai · healthydata.science |
Independent sources: getlatka.com · healthydata.science · startupintros.com
Technologies
| Name | Cluster | Risk | |
|---|---|---|---|
| AI bioprocess optimization as SaaS | digital-it | Low | → |
Compiled by BIOECON from primary sources.
Compliance
Bioecon is an information intermediary; it is not a regulator, a certification body, or a legal advisor. When working with public-sector customers (procurement under 44-FZ / 223-FZ), Bioecon acts solely as an independent analytical platform, with no remuneration from suppliers.